EWTX — Edgewise Therapeutics Balance Sheet
0.000.00%
- $1.55bn
- $1.08bn
- 38
- 24
- 20
- 16
Annual balance sheet for Edgewise Therapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
---|---|---|---|---|---|
Period Length: | — | — | — | — | — |
Source: | PROSPECTUS | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Cash and Equivalents | |||||
Short Term Investments | |||||
Cash and Short Term Investments | 129 | 281 | 352 | 318 | 470 |
Prepaid Expenses | |||||
Total Current Assets | 130 | 284 | 357 | 327 | 475 |
Gross Property, Plant And Equipment | |||||
Accumulated Depreciation | |||||
Net Property, Plant And Equipment | 0.516 | 0.912 | 9.85 | 12.7 | 11.1 |
Other Long Term Assets | |||||
Total Assets | 131 | 285 | 367 | 340 | 487 |
Accounts Payable | |||||
Accrued Expenses | |||||
Notes Payable / Short Term Debt | |||||
Total Current Liabilities | 4.34 | 10.5 | 16.6 | 16.8 | 23.9 |
Total Long Term Debt | |||||
Total Debt | |||||
Total Other Liabilities | |||||
Total Liabilities | 4.34 | 10.8 | 20.4 | 21.2 | 27.6 |
Redeemable Preferred Stock | |||||
Common Stock | |||||
Additional Paid In Capital | |||||
Retained Earnings (Accumulated Deficit) | |||||
Other Equity | |||||
Total Equity | 127 | 274 | 347 | 319 | 459 |
Total Liabilities & Shareholders' Equity | 131 | 285 | 367 | 340 | 487 |
Total Common Shares Outstanding |